NL2027065B1 - Hybridoma cell strain secreting monoclonal antibody against tobacco ringspot virus, antibody therefrom and antibody preparation method thereof - Google Patents

Hybridoma cell strain secreting monoclonal antibody against tobacco ringspot virus, antibody therefrom and antibody preparation method thereof Download PDF

Info

Publication number
NL2027065B1
NL2027065B1 NL2027065A NL2027065A NL2027065B1 NL 2027065 B1 NL2027065 B1 NL 2027065B1 NL 2027065 A NL2027065 A NL 2027065A NL 2027065 A NL2027065 A NL 2027065A NL 2027065 B1 NL2027065 B1 NL 2027065B1
Authority
NL
Netherlands
Prior art keywords
monoclonal antibody
variable region
ser
antibody
ringspot virus
Prior art date
Application number
NL2027065A
Other languages
Dutch (nl)
Inventor
Yu Xiaoping
Fu Huilan
Li Changjie
Sun Kai
Liu Yi
Liu Guangfu
Zhang Pengjun
Fu Xianshu
Yang Qianqian
Original Assignee
Univ Jiliang China
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Jiliang China filed Critical Univ Jiliang China
Priority to NL2027065A priority Critical patent/NL2027065B1/en
Application granted granted Critical
Publication of NL2027065B1 publication Critical patent/NL2027065B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention provides a hybridoma cell strain secreting monoclonal antibody against Tobacco ringspot virus as well as antibody therefrom and antibody preparation method thereof, wherein: BALB/c mice are immunized with the recombinant expression of full-length tobacco ringspot virus coat protein TRSV (523aa) to obtain a hybridoma cell strain, and the cell strain which can produce monoclonal antibody specifically recognize the Tobacco ringspot virus coat protein are screened, then monoclonal antibodies specifically recognizing Tobacco ringspot virus coat protein are obtained by ascites preparation method, the lengths of heavy chain variable region and light chain variable region of this monoclonal antibody are respectively 185 and 121 amino acids; the yield of monoclonal antibody is 500 ~ 5000 mg/l ascites, the purity is 85% ~ 99.5%. The monoclonal antibody of the present invention has a characteristic of specifically recognizing Tobacco ringspot virus coat protein, and it has a broad application prospect in terms of Tobacco ringspot virus entry-exit inspection and quarantine.

Description

HYBRIDOMA CELL STRAIN SECRETING MONOCLONAL ANTIBODY AGAINST TOBACCO RINGSPOT VIRUS, ANTIBODY THEREFROM AND ANTIBODY PREPARATION METHOD THEREOF
TECHNICAL FIELD The present invention relates to a monoclonal antibody, particularly relates to a hybridoma cell strain secreting monoclonal antibody against Tobacco ringspot virus (TRSV) as well as antibody therefrom and antibody preparation method thereof.
BACKGROUND Tobacco ringspot virus (TRSV) is a member of virus Comoviridae, its virion is an icosahedron with equal diameter, the diameter is about 29 nm. TRSV can infect 300 types of crops such as soybean, apple, and tobacco. At present, international quarantine method for TRSV comprises SEM observation, biological method, serological test and molecular biology method. Because TRSV is a spherical virus with a diameter of 29 nm and virus content in the sample is low, it is difficult to be observed and identified under the electron microscope; inoculation and identification of the host require a special isolated greenhouse, and spend a long time, and masking of symptom of the virus tends to affect identification result. The serological method is necessary means for rapid detection of plant virus, and current virus detection at port rely on purchase of imported antiserum, being expensive, but in China there has being no reports on TRSV serum detection kit for imported plant seeding.
The present invention screens and obtains a monoclonal-antibody-secreting cell strain, by using TRSV coat protein as the detection target, via the complete gene fusion expression, isolation and purification of TRSV coat protein, as well as a series of steps such as cross-linked immunity of mouse, cell fusion, antibody activity detection. Sequence of antigen recognition region in antibody gene is obtained by RT-PCR method. Finally, monoclonal antibodies of which the sequence specifically recognizing target antigen being known is obtained a cell strain producing this antibody and corresponding antibody production method. Compared to the method for obtaining monoclonal antibody by immunizing mouse with purified virion, The present invention does not require the active virus sample, and can directly obtain the virus coat protein by the whole gene synthesis and fusion expression method, and the acquisition of antigen is not restricted by the source of carrying virus samples, nor does it violate the operation scope of imported inspection and quarantine objects. The variable region sequence of monoclonal antibody is clear, and does not repeat with the existing antibody sequence, and it has clear and easy to be recognized compared to the antibodies already on the market and related investigated and reported antibodies.
SUMMARY OF THE INVENTION The technical problem to be solved by the present invention is to provide a monoclonal antibody against TRSV, the monoclonal antibody has a reaction specificity that recognizes and binds with TRSV coat protein, and lack of binding specificity to other viruses and plant tissue, and lays a foundation for further research and development of TRSV serum detection kit.
The present invention firstly discloses a monoclonal antibody against TRSV, the sequence of heavy chain variable region of this antibody is as shown in SEQ ID NO:1, the sequence of light chain variable region is as shown in SEQ ID NO:2.
The lengths of the heavy chain variable region and the light chain variable region in this monoclonal antibody are respectively 185 and 121 amino acids.
As a preferred embodiment of the present invention, the nucleotide sequences encoding said heavy chain and light chain variable region are respectively as shown in SEQ ID NO:3 and SEQ ID NO:4.
Said monoclonal antibody is prepared by ascites inducing method, its yield is 500-5000 mg/l, and purity is 85%~99.5%.
The present invention also discloses a hybridoma cell strain secreting monoclonal antibody against TRSV, the hybridoma cell strain is collected at China General Microbiological Culture Collection, and the accession number is: CGMCC20795.
The present invention also discloses application of said monoclonal antibody against TRSV virus in preparation of TRSV detection reagent or kit.
Said monoclonal antibodies against TRSV are prepared by the steps as follows: Finding out the RNA sequence of TRSV coat protein from Genbank (sequence number: KP144328.1), the length of which was 1545bp; The recombinant gene sequence was obtained by sequence optimization and separation tag fusion, as shown in SEQ ID NO: 5, and the corresponding protein sequence was shown in SEQ ID NO: 6.
SEQ ID NO: 5 was inserted into PET28b vector and expressed in the strain of E. coli BL21(DE3). The induced expression conditions were LB liquid medium, with IPTG (Isopropyl- beta-D-thiogalactopyranoside) at 1mM, at 16 °C for 16h, and 200 rpm. The fusion protein TRSV was isolated and purified by Ni-ion affinity chromatography.
Immunizing mice with the fusion protein TRSV,; Preparing hybridoma cells and screening cell strain producing antibody specifically recognizing SEQ ID NO:8 protein; By RT-PCR method, cloning and determining the sequences of heavy chain and light chain variable regions of the monoclonal antibody in the monoclonal antibody cell strain; By using the ascites inducing method, preparing monoclonal antibodies which can recognize SEQ ID NO:6 protein and show positive reaction to the sample carrying TRSV,;
By using ammonium sulphate precipitation and protein G affinity chromatography method, purifying the monoclonal antibodies according to the present invention.
Preparation process of the monoclonal antibodies by ascites inducing method specifically comprises the steps as follows: 8 ~ 15 week old BALB/c mice are injected intraperitoneally with a sterilized paraffin at 0.1 ~ 0.5 ml/mouse; After 5 ~ 10 days, intraperitoneally inoculated with hybridoma cells suspended in PBS at 5x105- 5x 108/mouse; After 5 — 10 days, the ascites is collected 2 ~ 4 times; The ascites is centrifuged at 1000xg for 10 minutes, uppermost adipose tissue is sucked off, cell components and precipitate are removed, and supernatant was collected;\ 3 ml of ascites supernatant is taken, after centrifugation, precipitation, redissolution, and recentrifugation, it is concentrated to 5 ml; The concentrated solution is passed through a protein G purifying resin, eluted with 10 ~ 15 column volumes of pre-eluent, monoclonal antibodies are eluted with 5 ~ 10 column volumes of elution buffer, after concentration, to obtain the monoclonal antibodies of the present invention.
Preferably, the pre-eluant in said step (6) includes 0.1 ~ 0.15 M NaCl and 10 ~ 40 mM Na:HPO,, pH is 7.0; said elution buffer is 0.1 - 0.3 M glycine, and pH is 3.0.
The term “monoclonal antibody” as used in the present invention refers to an antibody obtained from a substantially homogenous cell population, namely individual antibodies included in this population are same, except for a few possible naturally occurring mutations. The monoclonal antibody is directed against a single antigen site with high specificity. The monoclonal antibody according to the present invention specifically recognizes the fusion protein shown in SEQ ID NO:6 derived from TRSV coat protein The present invention has the following beneficial effects: the monoclonal antibody against TRSV according to the present invention underwent antibody titre determination and ELISA, the results indicate that the monoclonal antibody recognizing the fusion protein shown in SEQ ID NO:6 has a reaction specificity with TRSV, and can be used as an antibody for TRSV detection, which can lay a good foundation for subsequent development of TRSV serum detection kit, and serve for work needs of entry-exit inspection and quarantine.
DETAILED DESCRIPTION The present invention is further explained by the following examples.
Example 1 (1) the RNA sequence of TRSV coat protein from Genbank (sequence number: KP144328.1), the length of which was 1545bp; (2) The recombinant gene sequence was obtained by sequence optimization and separation tag fusion, as shown in SEQ ID NO: 5, and the corresponding protein sequence was shown in SEQ ID NO: 6.
(3) SEQ ID NO: 5 was inserted into PET28b vector and expressed in the strain of E. coli BL21(DE3). The induced expression conditions were LB liquid medium, with IPTG (Isopropyl- beta-D-thiogalactopyranoside) at 1mM, at 16°C for 16h, and 200 rpm. The fusion protein TRSV was isolated and purified by Ni-ion affinity chromatography.
{4) Immunization of mice (5) Preparation of hybridoma cells (6) Cloning of hybridoma cells (by limited dilution method) (7) Preparation of monoclonal antibodies by ascites inducing method Example 2 The steps (1)-(6) of Example 2 are same as Example 1.
(7) Preparation of monoclonal antibodies by ascites inducing method 15 week old BALB/c mice were injected intraperitoneally with sterilized paraffin at 0.5 ml/mouse; After 10 days, intraperitoneally inoculated with hybridoma cells suspended in PBS at 5x10%mouse; After 10 days, the ascites was collected 4 times; The ascites was centrifuged at 1000xg for 10 minutes, uppermost adipose tissue was sucked off, then cell components and other precipitate were removed, and supernatant was collected; 3 ml of ascites supernatant was taken, after centrifugation, precipitation, redissolution, and recentrifugation, it was concentrated to 5 ml; the concentrated solution was passed through protein G purifying resin, eluted with 15 column volumes of pre-eluent (00.15 M NaCl, 40 mM Na;HPO., pH 7.0), monoclonal antibodies were eluted with 10 column volumes of elution buffer (0.3 M glycine, pH 3.0), after being concentrated, to obtain the monaclonal antibodies of the present invention, the yield was 500 mg/l ascites, the purity was 87.2%, the Tobacco leaves carrying inactivated TRSV were detected, the detection signal was positive. Reaction of this antibody to Tobacco sample not infected by TRSV was negative, and reactions to Tobacco mosaic virus, Arabis mosaic virus, Bean pod mottle virus etc. were negative.
Example 3 Steps (1) ~ (6) of Example 3 are same as Example 1. Preparation of monoclonal antibodies by ascites inducing method 5 11.5-week old BALB/c mice were taken and injected intraperitoneally with sterilized paraffin at 0.3 ml/mouse; After 7 days, inoculated intraperitoneally with hybridoma cells suspended in PBS at
1.25x108/mouse; After 7 days, ascites was collected 3 times; Ascites was centrifuged at 1000 x g for 10 minutes, the uppermost adipose tissue was sucked off, the cell components and other precipitates were removed, and a supernatant was collected; 3 ml of ascites supernatant was taken, after centrifugation, precipitation, redissolution, recentrifugation, it was concentrated to 5 ml; The concentrated solution was passed through protein G purifying resin, monoclonal antibodies were eluted with 13 column volumes of pre-eluant (0.125 M NaCl, 25 mM Na2HPO,, pH 7.0), and eluted with 7 column volumes of elution buffer (0.2 M glycine, pH 3.0), after being concentrated, the monoclonal antibodies of the present invention were obtained, the yield was 500~5000 mg/l ascites, the purity was 93.5%, the tobacco leaves carrying inactivated TRSV were detected, the detection signal was positive. Reaction of this antibody to tobacco sample not infected by TRSV of was negative, and reactions to Tobacco mosaic virus, T7 bacteriophage, Arabis mosaic virus, and Bean pod mottle virus were negative.
SEQUENCE LISTING <110> China Jiliang University <120> Hybridoma cell strain secreting monoclonal antibody against Tobacco ringspot virus as well as antibody and antibody preparation method thereof <130> BJS - Hybridoma NL <160> © <170> PatentIn version 3.5 <210> 1 <211> 185 <212> PRT <213> Artificial Sequence <220> <223> Heavy chain variable region of a monoclonal antibody against TRSV <400> 1 Met Val Gln Leu Gln Gln Ser Gly Thr Val Leu Leu Ala Arg Pro Gly 1 5 10 15 Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Ser Phe Gly Thr
Ser Tyr Trp Met His Trp Val Lys Gln Arg Pro Gly Gly Gln Gly Leu 40 45 Glu Trp Ile Gly Ala Ile Tyr Pro Gly Lys Asn Ser Asp Thr Asn Tyr 50 55 60 Asn Gln Lys Phe Lys Gly Lys Ala Lys Leu Thr Ala Val Thr Ser Ala 65 70 75 80 Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Thr Asn Glu Asp Ser Ala 85 90 95 Val Tyr Tyr Cys Thr Arg Leu Ser Met Leu Gly Arg Ser Tyr Tyr Phe 100 105 110 Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser Ala Lys Ala 115 120 125 Thr Pro Pro Ser Val Tyr Pro Leu Ala Pro Gly Cys Gly Asp Thr Thr 130 135 140 Gly Ser Ser Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu 145 150 155 160
Ser Val Thr Val Thr Trp Asn Ser Gly Ser Leu Ser Ser Ser Val His 165 170 175 Thr Phe Pro Asp Ser Cys Ser Phe Thr 180 185 <210> 2 <211> 121 <212> PRT <213> Artificial Sequence <220> <223> Light chain variable region of a monoclonal antibody against TRSV <400> 2 Met Ala Cys Arg Pro Ser Ile Val Leu Tyr Thr Gln Ser Pro Ser Ser 1 5 10 15 Leu Ala Met Ser Val Gly Gln Arg Tyr Val Thr Met Ser Cys Lys Ser
Ser Gln Ser Leu Leu Asn Ser Ser Asn Gln Lys Asn Tyr Cys Leu Ala 40 45 Trp Cys Gln Gln Arg Pro Gly Gln Ser Pro Lys Leu Leu Glu Ser Gly 50 55 60 Val Pro Asp Arg Phe Ile Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu 65 70 75 80 Thr Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Asp Tyr Phe Cys Gln 85 90 95 Leu His Tyr Ser Thr Pro His Val Arg Cys Trp Glu Gln Ala Gly Asp 100 105 110 Pro Thr Lys Leu Val Arg Ala Thr Arg 115 120 <210> 3 <211> 555 <212> DNA <213> Artificial Sequence <220> <223> Nucleotide sequence encoding the heavy chain variable region of a monoclonal antibody against TRSV <400> 3 atggtacaac tgcaacaatc tggtaccgtt ctgctggcac gtcctggtgc atccgtgaaa 60 atgagctgca aagcaagcgg ctactccttc ggtactagct actggatgca ctgggttaag 120 cagcgtccgg gtggccaggg tctggaatgg atcggtgcaa tctatccggg caaaaatagc 180 gacacgaact acaatcagaa attcaaaggc aaggctaaac tgaccgcggt aacctccgcc 240 tctactgcat acatggagct gtccagcctg accaatgaag attccgcggt ttactattgc 300 acccgcctgt ctatgctggg tcgtagctac tattttgact attggggcca aggtaccacc 360 ctgaccgttt ctagcgctaa agctacgcca ccgtccgtgt atccgctggc tccaggttgt 420 ggtgatacca cgggttctag cgttaccctg ggttgcctgg ttaaaggcta cttcccagag 480 agcgttacgg tcacctggaa ttccggtagc ctgtccagct ccgtgcatac cttcccagat 540 agctgctcct tcacg 555 <210> 4 <211> 363 <212> DNA <213> Artificial Sequence <220> <223> Nucleotide sequence encoding the light chain variable region of a monoclonal antibody against TRSV <400> 4 atggcgtgtc gcccttcgat tgtgctgtat actcaatctc catcctccct ggctatgtca 60 gtaggacaga ggtatgtcac tatgagctgc aagtccagtc agagcctttt aaatagtagc 120 aatcaaaaga actattgctt ggcctggtgc cagcagagac caggacagtc tcctaaactt 180 ctggaatctg gggtccctga tcgcttcata ggcagtggat ctgggacaga tttcactctt 240 accatcagca gtgtgcaggc tgaagacctg gcagattact tctgtcagct acattatagc 300 actcctcacg ttcggtgctg ggaacaagct ggagatccaa cgaagcttgt aagggcgaca 360 cgc 363 <210> 5 <211> 1572 <212> DNA <213> Artificial Sequence <220> <223> Recombinant gene sequence of TRSV coat protein (Genbank KP144328.1) <400> 5 atggccgctg tgacggttgt tcccgatccc acttgttgtg ggacattgtc ctttaaggtt 60 cccaaagatg cgaagaaagg aaagcatctt ggaacttttg acattcggca agccattatg 120 gaatatggtg gtttgcattc ccaagaatgg tgtgcaaagg gcattgttaa tcccactttt 180 acagtgagga tgcatgcccc acgcaacgcc tttgcaggtt tgtctatagc gtgcaccttt 240 gatgattaca aacgcataga cttaccagcg cttgggaatg aatgtcctcc ctccgagatg 300 tttgaactgc ctaccaaggt tttcatgctt aaagatgcag atgtgcatga atggcagttc 360 aactatgggg aacttacagg acatgggttg tgcaattggg caaatgtagt tacccagccc 420 acattgtact tttttgttgc gtccacaaat caagtgacga tggctgctga ttggcagtgt 480 attgttacta tgcatgtgga catggggccc gtcattgatc gttttgagtt agatccaact 540 atgacgtggc ctattcaatt gggtgacact ttcgccattg atagatatta tgaggcgaaa 600 gaaattaaac ttgacgggtc aacctccatg ttgtctatat cttataattt tggaggtccc 660 gtcaagcatt ctaagaaaca tgccatttca tattcccggg cagttatgtc taggaatctt 720 gggtggtctg gcactataag cggaagtgtc aagagtgttt cttctttatt ttgtaccgct 780 tettttgtta tttttccatg ggaacacgaa gcacctccaa ccttacgtca ggtgttatgg 840 ggcccacatc agataatgca cggagatggc caatttgaaa ttgctatcaa aactcgtctt 900 cattcagctg ctacaactga agaagggttt ggtagacttg gtatactccc gctttctggg 960 cctatagctc ctgatgcaca tgttggatcg tacgagttta ttgtacatat agacacttgg 1020 cgacccgact ctcaggtgca tcctcccatg ttttctagtg cggagcttta taattggttc 1080 actttaacca atttgaaacc agatgcgaac actggcgtag tcaactttga tattcccgga 1140 tacatccatg acttcgcctc taaggacgca actgtgacgc tcgcatcaaa tcccctctct 1200 tggcttgtcg cagctactgg ctggcattat ggtgaggtgg atctctgcat ctcctggtca 1260 aggtccaaac aggcccaggc tcaggagggt agtgtttcca ttaccactaa ttatagagat 1320 tggggtgctt actggcaagg ccaggcccgg atttatgatt tgcggcgtac tgaagcggaa 1380 attcccatct tcttgggttc ttacgctggt gcgacgccat ctggtgcctt gggtaagcaa 1440 aactatgtcc ggatttcaat tgtcaatgct aaggacatag ttgcactgcg agtgtgtttg 1500 cgacccaaat ctataaagtt ctggggtcgc tccgccactt tgtttctcga gcaccaccac 1560 caccaccact ga 1572 <210> © <211> 523 <212> PRT <213> Artificial Sequence <220> <223> Recombinant protein sequence derived from TRSV coat protein (Genbank KP144328.1) <400> © Met Ala Ala Val Thr Val Val Pro Asp Pro Thr Cys Cys Gly Thr Leu 1 5 10 15
Ser Phe Lys Val Pro Lys Asp Ala Lys Lys Gly Lys His Leu Gly Thr
Phe Asp Ile Arg Gln Ala Ile Met Glu Tyr Gly Gly Leu His Ser Gln 40 45 Glu Trp Cys Ala Lys Gly Ile Val Asn Pro Thr Phe Thr Val Arg Met 50 55 60 His Ala Pro Arg Asn Ala Phe Ala Gly Leu Ser Ile Ala Cys Thr Phe 65 70 75 80 Asp Asp Tyr Lys Arg Ile Asp Leu Pro Ala Leu Gly Asn Glu Cys Pro 85 90 95 Pro Ser Glu Met Phe Glu Leu Pro Thr Lys Val Phe Met Leu Lys Asp 100 105 110 Ala Asp Val His Glu Trp Gln Phe Asn Tyr Gly Glu Leu Thr Gly His 115 120 125 Gly Leu Cys Asn Trp Ala Asn Val Val Thr Gln Pro Thr Leu Tyr Phe 130 135 140 Phe Val Ala Ser Thr Asn Gln Val Thr Met Ala Ala Asp Trp Gln Cys 145 150 155 160 Ile Val Thr Met His Val Asp Met Gly Pro Val Ile Asp Arg Phe Glu 165 170 175 Leu Asp Pro Thr Met Thr Trp Pro Ile Gln Leu Gly Asp Thr Phe Ala 180 185 190 Ile Asp Arg Tyr Tyr Glu Ala Lys Glu Ile Lys Leu Asp Gly Ser Thr 195 200 205 Ser Met Leu Ser Ile Ser Tyr Asn Phe Gly Gly Pro Val Lys His Ser 210 215 220 Lys Lys His Ala Ile Ser Tyr Ser Arg Ala Val Met Ser Arg Asn Leu 225 230 235 240 Gly Trp Ser Gly Thr Ile Ser Gly Ser Val Lys Ser Val Ser Ser Leu 245 250 255
Phe Cys Thr Ala Ser Phe Val Ile Phe Pro Trp Glu His Glu Ala Pro 260 265 270 Pro Thr Leu Arg Gln Val Leu Trp Gly Pro His Gln Ile Met His Gly 275 280 285 Asp Gly Gln Phe Glu Ile Ala Ile Lys Thr Arg Leu His Ser Ala Ala 290 295 300 Thr Thr Glu Glu Gly Phe Gly Arg Leu Gly Ile Leu Pro Leu Ser Gly 305 310 315 320 Pro Ile Ala Pro Asp Ala His Val Gly Ser Tyr Glu Phe Ile Val His 325 330 335 Ile Asp Thr Trp Arg Pro Asp Ser Gln Val His Pro Pro Met Phe Ser 340 345 350 Ser Ala Glu Leu Tyr Asn Trp Phe Thr Leu Thr Asn Leu Lys Pro Asp 355 360 365 Ala Asn Thr Gly Val Val Asn Phe Asp Ile Pro Gly Tyr Ile His Asp 370 375 380 Phe Ala Ser Lys Asp Ala Thr Val Thr Leu Ala Ser Asn Pro Leu Ser 385 390 395 400 Trp Leu Val Ala Ala Thr Gly Trp His Tyr Gly Glu Val Asp Leu Cys 405 410 415 Ile Ser Trp Ser Arg Ser Lys Gln Ala Gln Ala Gln Glu Gly Ser Val 420 425 430 Ser Ile Thr Thr Asn Tyr Arg Asp Trp Gly Ala Tyr Trp Gln Gly Gln 435 440 445 Ala Arg Ile Tyr Asp Leu Arg Arg Thr Glu Ala Glu Ile Pro Ile Phe 450 455 460 Leu Gly Ser Tyr Ala Gly Ala Thr Pro Ser Gly Ala Leu Gly Lys Gln 465 470 475 480 Asn Tyr Val Arg Ile Ser Ile Val Asn Ala Lys Asp Ile Val Ala Leu 485 490 495 Arg Val Cys Leu Arg Pro Lys Ser Ile Lys Phe Trp Gly Arg Ser Ala 500 505 510
Thr Leu Phe Leu Glu His His His His His His 515 520

Claims (7)

CONCLUSIESCONCLUSIONS 1. Een monoklonaal antilichaam tegen het tabaksringvlekvirus, waarbij de sequentie van het variabele gebied van de zware keten van het antilichaam is zoals weergegeven in SEQ ID NO:1, en de sequentie van het variabele gebied van de lichte keten is zoals weergegeven in SEQ ID NO:2.A monoclonal antibody against tobacco ringspot virus, wherein the sequence of the variable region of the antibody heavy chain is as shown in SEQ ID NO:1, and the sequence of the light chain variable region is as shown in SEQ ID NO:2. 2. Het monoklonale antilichaam volgens conclusie 1, waarin de lengtes van het variabele gebied van de zware keten en van het variabele gebied van de lichte keten van het monoklonale antilichaam respectievelijk 185 en 121 aminozuren bedragen.The monoclonal antibody of claim 1, wherein the lengths of the heavy chain variable region and the light chain variable region of the monoclonal antibody are 185 and 121 amino acids, respectively. 3. Een gen dat codeert voor een monoklonaal antilichaam volgens conclusie 1, waarbij het gen een nucleotidesequentie omvat die codeert voor het variabele gebied van de lichte keten en een nucleotidesequentie die codeert voor het variabele gebied van de zware keten, waarbij de nucleotidesequentie die codeert voor het variabele gebied van de zware keten is zoals is weergegeven in SEQ ID NO:3, en de nucleotidesequentie die codeert voor het variabele gebied van de lichte keten is zoals is weergegeven in SEQ ID NO:4.A gene encoding a monoclonal antibody according to claim 1, wherein the gene comprises a nucleotide sequence encoding the light chain variable region and a nucleotide sequence encoding the heavy chain variable region, wherein the nucleotide sequence encoding the heavy chain variable region is as shown in SEQ ID NO:3, and the nucleotide sequence encoding the light chain variable region is as shown in SEQ ID NO:4. 4. Een lijn van hybridoma - cellen die monoklonaal antilichaam tegen het tabaksringspotvirus uitscheiden, zoals gedeponeerd bij het China General Microbiological Culture Collection Center, met het toegangsnummer van CGMCC20795.4. A line of hybridoma cells secreting monoclonal antibody to tobacco ringspot virus, as deposited with the China General Microbiological Culture Collection Center, with the accession number of CGMCC20795. 5. Een werkwijze voor het bereiden van het monoklonale antilichaam volgens conclusie 1, waarbij de werkwijze de volgende stappen omvat: (1) intraperitoneaal injecteren van 8 ~ 15 weken oude BALB/c muizen met 0,1 ~ 0,5 ml/muis gesteriliseerde paraffine; (2) na 5 ~ 10 dagen het intraperitoneaal inoculeren van de hybridoma - cellen volgens conclusie 4, gesuspendeerd in PBS, in een hoeveelheid van 5 x 105 ~ 5 x 109 / muis; (3) na 5 ~ 10 dagen het samenvoegen van 2 ~ 4 keer verzameld ascites; (4) het centrifugeren van de ascites bij 1000 x g gedurende 10 minuten, het opzuigen van het boven liggende vetweefsel, het verwijderen van celbestanddelen en neerslag, en het verzamelen van een bovenstaande vloeistof, (5) het nemen van 3 ml van bovenstaande ascitesvloeistof, na centrifugeren, neerslaan, opnieuw oplossen, en opnieuw centrifugeren, concentreren op 5 ml; (6) het passeren van de geconcentreerde oplossing door een eiwit G - zuiveringshars, en eluéren met 10 ~ 15 kolomvolumina van pre-eluéns, eluéren van de monoklonale antilichamen met 5 ~ 10 kolomvolumina van de elutiebuffer, na te zijn geconcentreerd, waardoor van de monoklonale antilichamen worden verkregen.A method for preparing the monoclonal antibody of claim 1, wherein the method comprises the following steps: (1) intraperitoneally injecting 8~15 week old BALB/c mice with 0.1~0.5ml/mouse sterilized paraffin; (2) after 5 ~ 10 days, intraperitoneally inoculating the hybridoma cells according to claim 4, suspended in PBS, in an amount of 5 x 10 5 ~ 5 x 10 9 /mouse; (3) after 5 ~ 10 days merging of 2 ~ 4 times collected ascites; (4) centrifuging the ascites at 1000 x g for 10 min, aspirating the overlying adipose tissue, removing cell components and precipitate, and collecting a supernatant, (5) taking 3 ml of the ascitic supernatant, after centrifugation, precipitate, redissolve, and recentrifuge, concentrate to 5 ml; (6) passing the concentrated solution through a protein G purification resin, and eluting with 10 ~ 15 column volumes of pre-eluents, eluting the monoclonal antibodies with 5 ~ 10 column volumes of the elution buffer, after being concentrated, leaving the monoclonal antibodies are obtained. 6. De werkwijze voor het bereiden volgens conclusie 5, waarbij het pre-eluéns in genoemde stap (6) 0,1 ~ 0,15 M NaCl en 10 ~ 40 mM Na2HPO. omvat en de pH 7,0 ervan bedraagt; waarbij de elutiebuffer 0,1 ~ 0,3 M glycine is , en de pH daarvan 3,0 bedraagt.The preparation method according to claim 5, wherein the pre-eluent in said step (6) is 0.1 ~ 0.15 M NaCl and 10 ~ 40 mM Na2HPO. and its pH is 7.0; wherein the elution buffer is 0.1 ~ 0.3 M glycine, and the pH thereof is 3.0. 7. Toepassing van het monoklonale antilichaam tegen tabaksringvlekvirus volgens conclusie 1 voor het bereiden van een detectiereagens of detectieset voor tabaksringvlekvirus.Use of the monoclonal antibody to tobacco ringspot virus according to claim 1 for preparing a detection reagent or detection kit for tobacco ringspot virus.
NL2027065A 2020-12-08 2020-12-08 Hybridoma cell strain secreting monoclonal antibody against tobacco ringspot virus, antibody therefrom and antibody preparation method thereof NL2027065B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NL2027065A NL2027065B1 (en) 2020-12-08 2020-12-08 Hybridoma cell strain secreting monoclonal antibody against tobacco ringspot virus, antibody therefrom and antibody preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL2027065A NL2027065B1 (en) 2020-12-08 2020-12-08 Hybridoma cell strain secreting monoclonal antibody against tobacco ringspot virus, antibody therefrom and antibody preparation method thereof

Publications (1)

Publication Number Publication Date
NL2027065B1 true NL2027065B1 (en) 2021-10-22

Family

ID=74759429

Family Applications (1)

Application Number Title Priority Date Filing Date
NL2027065A NL2027065B1 (en) 2020-12-08 2020-12-08 Hybridoma cell strain secreting monoclonal antibody against tobacco ringspot virus, antibody therefrom and antibody preparation method thereof

Country Status (1)

Country Link
NL (1) NL2027065B1 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110845608A (en) * 2019-11-20 2020-02-28 中国计量大学 Tomato ringspot virus monoclonal antibody and preparation method thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110845608A (en) * 2019-11-20 2020-02-28 中国计量大学 Tomato ringspot virus monoclonal antibody and preparation method thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "PM 7/2 (2) Tobacco ringspot virus", PO BULLETIN: A JOURNAL OF REGULATORY PLANT PROTECTION, vol. 47, no. 2, 29 May 2017 (2017-05-29), GB, pages 135 - 145, XP055823749, ISSN: 0250-8052, Retrieved from the Internet <URL:https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fepp.12376> DOI: 10.1111/epp.12376 *

Similar Documents

Publication Publication Date Title
CN111153991A (en) Human SARS-CoV-2 monoclonal antibody and its preparation method and use
CN112062839A (en) Nano antibody based on novel coronavirus S protein S1 subunit and application thereof
CN113912710B (en) Monoclonal antibody for resisting novel coronavirus N protein and application thereof
EP2757111B1 (en) Anti-human norovirus gii antibody
CN113527476B (en) Novel nano antibody for resisting H5 subtype avian influenza virus and application thereof
CN114181308B (en) Procalcitonin antibody and application thereof
CN111793132A (en) Monoclonal antibody of human procalcitonin and preparation method and application thereof
CN110845608B (en) Tomato ringspot virus monoclonal antibody and preparation method thereof
CN111647055B (en) N protein for detecting novel coronavirus, preparation and application thereof
CN110885370B (en) Hybridoma cell strain secreting tomato ringspot virus monoclonal antibody, antibody thereof and antibody preparation method
CN110078821B (en) Sequence of enterovirus D group 68 type VP1 monoclonal antibody and application thereof
CN116082498A (en) Monoclonal antibody of monkey pox virus protein and application thereof
WO2024140618A1 (en) 1,3-β-D-GLUCAN BINDING PROTEIN, PREPARATION METHOD, AND USE
CN117964746A (en) Neutralizing antibody HY2 of A-type foot-and-mouth disease virus, preparation method and application thereof
CN117903300A (en) Neutralizing antibody HY1 of A-type foot-and-mouth disease virus, and preparation method and application thereof
NL2027065B1 (en) Hybridoma cell strain secreting monoclonal antibody against tobacco ringspot virus, antibody therefrom and antibody preparation method thereof
CN110887963B (en) PCV2 virus-like particle sandwich quantitative ELISA detection method and application thereof
CN112175072A (en) Monoclonal antibody ZJU5-01 for resisting H5 subtype avian influenza virus hemagglutinin protein and application thereof
CN112898422B (en) Tobacco ringspot virus monoclonal antibody and preparation method and application thereof
CN114295829B (en) Novel coronavirus antigen and total antibody combined detection kit and detection method
LU101592B1 (en) Hybridoma cell strain secreting monoclonal antibody against Tomato ringspot virus, antibody therefrom and antibody preparation method thereof
CN110894236B (en) Anti-aspergillus galactomannan monoclonal antibody and application thereof
CN113341141A (en) AlphaLISA detection kit for avian influenza virus H9 and detection method thereof
KR101294758B1 (en) Detecting method of CMV or GMO that tolerant to CMV
CN110702913A (en) Monoclonal antibody composition for quantitatively detecting coxiella burnetii I strain

Legal Events

Date Code Title Description
MM Lapsed because of non-payment of the annual fee

Effective date: 20240101